Alcon Agrees to Acquire LENSAR, Inc.
March 24, 2025
Alcon and LENSAR entered into a definitive merger agreement under which Alcon intends to acquire LENSAR for $14.00 per share in cash, plus a contingent value right that could add up to $2.75 per share. The total potential consideration is approximately $430 million, and the deal is expected to close in mid-to-late 2025 subject to customary approvals and LENSAR stockholder approval.
- Buyers
- Alcon
- Targets
- LENSAR, Inc.
- Industry
- Medical Devices
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Tarsus Pharmaceuticals Acquires Alkeus Pharmaceuticals
August 6, 2026
Biotechnology
Tarsus Pharmaceuticals agreed to acquire Alkeus Pharmaceuticals for approximately $450 million upfront—$270 million in cash and $180 million in Tarsus stock—with up to $350 million in milestone payments and tiered royalties. Tarsus completed the acquisition on September 4, 2026, adding worldwide rights to Alkeus’s Phase 3 Stargardt disease therapy, gildeuretinol (ALK-001), to expand its retina pipeline and eye-care portfolio.
-
Alcon Agrees to Acquire STAAR Surgical Company
October 15, 2025
Healthcare Services
Alcon entered into a definitive merger agreement to acquire STAAR Surgical Company for $28.00 per share in cash, valuing the deal at approximately $1.5 billion. The transaction includes STAAR’s EVO family of implantable collamer lenses (EVO ICL) and is expected to close in about six to 12 months, subject to regulatory approval and STAAR shareholder approval.
-
Alcon to Acquire LumiThera
July 7, 2025
Medical Devices
Alcon, a leader in eye care, plans to acquire LumiThera, which develops light-based therapies for ophthalmology, including its photobiomodulation (PBM) device for treating early and intermediate dry age-related macular degeneration (AMD). The acquisition is expected to close in the third quarter of 2025, subject to customary closing conditions and a LumiThera shareholder vote.
-
Alcon Acquires Aerie Pharmaceuticals, Inc.
August 22, 2022
Healthcare Services
Alcon entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, adding Rocklatan and Rhopressa commercial products along with AR-15512 and other ophthalmic pharmaceutical pipeline assets. The deal was funded with debt and was expected to close in Q4 2022, subject to customary approvals and conditions.
-
Luminar Technologies Acquires Freedom Photonics
March 21, 2022
Industrial Services
Luminar (Nasdaq: LAZR) announced it is acquiring Freedom Photonics, a high-performance laser chip and photonics components company used for lidar and other optical sensing applications. The all-stock deal follows years of collaboration and is expected to close in the second quarter, with Freedom Photonics’ leadership continuing to run and expand the business after closing.
-
ALPHAEON Acquires LENSAR
November 16, 2015
Medical Devices
ALPHAEON Corporation has agreed to acquire substantially all assets of LENSAR, Inc. in a transaction valued at up to $59 million in cash, stock and assumed debt. The deal brings LENSAR’s femtosecond cataract laser technology into ALPHAEON’s lifestyle healthcare portfolio and expands ALPHAEON’s ophthalmology offering for its global network of ophthalmologists.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.